Board of Directors

Gary W. Pace has served as our director since July 1994. Dr. Pace is a founder and director of QRxPharma, an ASX-listed clinical-stage specialty pharmaceutical company. In addition to ResMed, he serves as a Director of Transition Therapeutics, a NASDAQ and TSX-listed company developing new therapies and Pacira Pharmaceuticals (NASDAQ: PCRX), a specialty pharmaceutical company. He also chairs the Nominating and Governance Committee at Pacira. In 2011, he was named Director of the Year... 

Michael A. Quinn has served as a director since September 1992. Since April 1999, Mr. Quinn has been the Chief Executive Officer of Innovation Capital, an Australian/U.S. venture capital fund. From February 1992 to April 1999, he was a management and financial consultant. From July 1988 to January 1992, Mr. Quinn served as Executive Chairman of Phoenix Scientific Industries Limited, a manufacturer of health care and scientific products and listed on the Australian Stock Exchange. Befor... 

Christopher G. Roberts, Ph.D., has served as one of our directors since September 1992. He also served as a director from August 1989 to November 1990. Since February 2004 he has been chief executive officer and president of Cochlear Limited, an ASX-listed medical device company that is the global leader in implantable devices for the hearing impaired (e.g. cochlear implants). Between August 1992 and January 2004 he was ResMed's executive vice president responsible for European and Asi... 

Richard Sulpizio has served as a director since August 2005. He currently serves as President and Chief Executive Officer of Qualcomm Enterprise Services, a division of Qualcomm Incorporated responsible for mobile communications and services to the transportation industry. Mr. Sulpizio has held leadership positions, including President and COO, with Qualcomm for over 20 years. He served as a member of Qualcomm’s Board of Directors from 2000 until 2007. Before joining Qualcomm, Mr. Su... 

Ronald Taylor has served as a director since January 2005. Mr. Taylor is a director of Watson Pharmaceuticals, Inc., a NYSE-listed specialty pharmaceutical company, Red Lion Hotels Corp, a NYSE-listed hospitality company and Aethon Corp., a privately-held provider of robotic delivery systems for hospitals. Mr. Taylor is Chairman of the Board of EMN8 Corporation, a manufacturer of self-service terminals for quick service restaurants. From 2002 until 2005, he served as chairman of the Re... 

John Wareham has served as our director since January 2005. From September 1993 to January 2004 Mr. Wareham was the president of Beckman Coulter, Inc. a NYSE-listed biomedical company that develops and markets instruments, chemistries, software and supplies to simplify and automate laboratory processes. Mr. Wareham also served as chief executive officer from August 1998 to February 2005 and chairman from January 1999 to April 2005. Before joining Beckman Coulter in 1984, Mr. Wareham wa...